OKYO Pharma ’s Post

Watch: A conversation on the current landscape for capital markets and expected trends for 2024, with a particular focus on the healthcare and life sciences industry, including: -A summary of recent market activity. -Characteristics of life sciences companies that have successfully exited or raised capital. -Specific industries of investor focus. -Considerations for healthcare and life sciences companies preparing to go public. This Cooley Market Talks session will feature Goldman Sachs' Sonia Gupta + Cooley capital markets co-chairs, Charlie Kim and David Peinsipp. Register here for the virtual event or to receive the on-demand recording: https://bit.ly/3SGtPpF #CooleyMarketTalks #capitalmarkets #healthcare #lifesciences

📈 Sophie Smith, our talented Investment Analyst for the SGH Medical Technology and Emerging Companies Funds, shares her stock picks at the small end of the Australian healthcare market with Tom Richardson at The Australian Financial Review. 👇 👇 👇 Check out which companies she backs and why here: https://lnkd.in/gaQDJwKn #medtech #ASX #ASXSmallCompanies #equityinvesting

Exciting Trends in Life Sciences Private Equity The life sciences sector has been a key focus for private equity (PE) funds seeking innovative and recession-resistant opportunities. The latest insights from Bain's 2024 Global Healthcare Private Equity Report reveal intriguing dynamics in the industry. - Deal Value Dilemma: Despite consistent interest, private equity deal value in 2023 faced challenges in matching the heights of 2022, partly attributed to a biotech funding slowdown. However, a silver lining emerged as investors increasingly favored early-stage therapies and precommercial medical devices. - Global Forces at Play: The ripple effects of the Inflation Reduction Act (IRA) and the surge in investments in cell, gene, and RNA therapies are reshaping the landscape for service providers. Strategic considerations around drug negotiation provisions and evolving modalities are becoming pivotal for successful investments. - AI's Transformative Role: The article highlights the transformative impact of artificial intelligence (AI) in accelerating product development and commercialization within the life sciences sector. - Investor Implications: Investors are advised to navigate these trends with a blend of operational and commercial excellence, alongside scientific proficiency. The potential for lucrative returns exists, especially for those who can seize opportunities in the evolving landscape of advanced modalities and strategic outsourcing. Explore the Full Report: For a comprehensive dive into the trends shaping life sciences private equity, explore Bain's 2024 Global Healthcare Private Equity Report. #LifeSciences #PrivateEquity #HealthcareInnovation #InvestmentTrends #BainReport2024

We continue to see lots of opportunities in life sciences investing. While 2023 deal activity was down vs 2021 and 2022, the multi-year trend continues to be up and to the right. Find out more in our 2024 Global Healthcare Private Equity Report.

This week, our CEO Tim Pickett participated in H.C. Wainwright & Co., LLC's 26th Annual Global Investment Conference. Listen in as he shares an overview of our patient-first healthcare model and more. To view the full presentation, sign up here: https://lnkd.in/geqiY6hu #KindlyMD #Utah #Investors #HolisticMedicine #HolisticTreatments

If you are eligible and interested, or if you know anyone interested - I’d love to help you get signed up! More info in the attached post. #angelinvestors #mn #greatermsp #equity #groovegapital #twinignition

Discover key investment insights for the healthcare and life sciences industry in 2024. From addressing integration challenges to scaling solutions, find out what our experts believe is driving deal activity in this evolving sector: https://lnkd.in/ebkj6xRg

Great to host our latest Quarterly Life Sciences event today with Womble Bond Dickinson (UK) LLP Well done to Ben Foster (DipACB) our Sector Lead and Peter Snaith for putting together a great panel to discuss the funding landscape for Life Sciences business in the North East Thank you to Richard Faulkner Chris McCourt Sam Whitehouse Dr Mike Nicholds & @christian fellowes for their insightful presentations Key takeaways ✅In such an attractive sector, it's crucial to stay open to international sources of capital. ✅Funding can be challenging due to long routes to revenue and profitability, so building a strong management team early on, especially with an experienced CFO, is key to success. This ensures good information and data management, crucial for investors. ✅Spread your pitches wide as many funds struggle with deploying capital. ✅There's a growing appetite for services, diagnostics, and device businesses ✅Having clarity on funding stages, regulatory journey, and validation from sector peers is essential. ✅Having an advisor with a broad network can be a game-changer in navigating these challenges and opening up International Capital

Discover key investment insights for the healthcare and life sciences industry in 2024. From addressing integration challenges to scaling solutions, find out what our experts believe is driving deal activity in this evolving sector: https://lnkd.in/g5fhjTke

Discover key investment insights for the healthcare and life sciences industry in 2024. From addressing integration challenges to scaling solutions, find out what our experts believe is driving deal activity in this evolving sector: https://lnkd.in/eKq4xarW